A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease.

[1]  P. Kris-Etherton,et al.  Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. , 2007, The American journal of clinical nutrition.

[2]  C. Serhan,et al.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.

[3]  C. Serhan,et al.  Specialized Proresolving Mediators Enhance Human B Cell Differentiation to Antibody-Secreting Cells , 2012, The Journal of Immunology.

[4]  G. Bakris,et al.  Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent , 2013, Current Cardiology Reports.

[5]  C. Serhan,et al.  Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. , 2014, Cell metabolism.

[6]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Trevor A. Mori,et al.  Dietary n-3 PUFA and CVD: a review of the evidence , 2013, Proceedings of the Nutrition Society.

[8]  C. Serhan,et al.  Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. , 2012, The American journal of pathology.

[9]  K. Weylandt,et al.  Acetylsalicylic Acid Reduces the Severity of Dextran Sodium Sulfate-Induced Colitis and Increases the Formation of Anti-Inflammatory Lipid Mediators , 2013, BioMed research international.

[10]  R. Bowden,et al.  Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. , 2009, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[11]  Jiang He,et al.  Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. , 2002, Journal of the American Society of Nephrology : JASN.

[12]  R. Zatz,et al.  The inflammatory component in progressive renal disease--are interventions possible? , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  Christopher Y. Lu,et al.  Acute kidney injury: a conspiracy of toll-like receptor 4 on endothelia, leukocytes, and tubules , 2012, Pediatric Nephrology.

[14]  S. Hewitt,et al.  Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. , 2001, Kidney international.

[15]  Deeb N Salem,et al.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.

[16]  C. Serhan,et al.  Resolution phase lipid mediators of inflammation: agonists of resolution. , 2013, Current opinion in pharmacology.

[17]  G. Watts,et al.  The effects of ω3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial , 2009 .

[18]  M. Mansournia,et al.  The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial , 2014, European Journal of Clinical Pharmacology.

[19]  C. Edelstein,et al.  Mediators of Inflammation in Acute Kidney Injury , 2010, Mediators of inflammation.

[20]  V. Arroyo,et al.  Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S‐hydroxy‐DHA , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Trevor A. Mori,et al.  Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation[S] , 2014, Journal of Lipid Research.

[22]  Jiangning Song,et al.  Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation , 2012, The Journal of pathology.

[23]  M. Perretti,et al.  Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci: Receptor-Dependent Actions , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[24]  U. Baber,et al.  Patients with Chronic Kidney Disease/Diabetes Mellitus: The High-Risk Profile in Acute Coronary Syndrome , 2013, Current Cardiology Reports.

[25]  M. Laville,et al.  Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients. , 2013, Nutrition.

[26]  C. Serhan,et al.  Resolvins and protectins in inflammation resolution. , 2011, Chemical reviews.

[27]  G. Watts,et al.  Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. , 2003, Atherosclerosis.

[28]  Song‐Pyo Hong,et al.  Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury , 2013, Front. Immun..

[29]  Trevor A. Mori,et al.  Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. , 2012, Clinical chemistry.

[30]  R. Wander,et al.  Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. , 2003, The Journal of nutritional biochemistry.

[31]  J. Imig,et al.  Immune and inflammatory role in renal disease. , 2013, Comprehensive Physiology.

[32]  N. Palaniyar,et al.  NET balancing: a problem in inflammatory lung diseases , 2013, Front. Immun..

[33]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  W. Harris,et al.  n-3 Fatty acids and cardiovascular disease. , 2004, The American journal of clinical nutrition.

[35]  Marcello Tonelli,et al.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study , 2012, The Lancet.

[36]  R. J. Henderson,et al.  Marine (n-3) polyunsaturated fatty acids , 1995 .

[37]  N. Isbel,et al.  Modification of cardiovascular risk in hemodialysis patients: An evidence‐based review , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[38]  A. Vatankhah,et al.  Effect of treatment with omega-3 fatty acids on C-reactive protein and tumor necrosis factor-alfa in hemodialysis patients. , 2012, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[39]  J. Duffield,et al.  Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury1 , 2006, The Journal of Immunology.